Patents Examined by Lester L. Lee
  • Patent number: 5376637
    Abstract: There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.
    Type: Grant
    Filed: April 16, 1992
    Date of Patent: December 27, 1994
    Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.
    Inventors: Kiichi Sawai, Masayasu Kurono, Takahiko Mitani, Makoto Sato, Haruo Takahashi, Hiroyuki Ohwaki
  • Patent number: 5374618
    Abstract: This invention relates to human gene related peptide pharmaceutical compositions containing the peptide and the method of treating hypertension with said pharmaceutical composition.
    Type: Grant
    Filed: February 14, 1985
    Date of Patent: December 20, 1994
    Assignee: Celltech Limited
    Inventors: Roger K. Craig, Mark R. Edbrooke
  • Patent number: 5374713
    Abstract: Peptide inhibitors of phospholipase A.sub.2 from inflammatory sites having the amino acid sequence given in formula SEQ. I.D.
    Type: Grant
    Filed: June 18, 1992
    Date of Patent: December 20, 1994
    Assignee: Teijin Limited
    Inventors: Yorimasa Suwa, Atsushi Imaizumi, Masahiro Okada, Chieko Azuma, Ichiro Kudo, Keizo Inoue
  • Patent number: 5371186
    Abstract: The present invention provides novel peptides of the formula R.sub.1 -(A-B-C).sub.n -R, where R.sub.1 and R are independently H or an amino acid residue or a fatty acid residue; A is an amino acid residue selected from the group consisting of Lys, Arg, and His; B is an amino acid selected from the group consisting of Phe, Tyr, and Trp; C is an amino acid selected from the group consisting of Leu, Ile and Val; n is an integer of 1-100. The peptides are used inter alia for the prevention and/or treatment of septic shock, for the detection of endotoxin and the preparation of antigenic complexes of Lipid A.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: December 6, 1994
    Assignee: Biosynth S.r.l.
    Inventor: Massimo Porro
  • Patent number: 5369094
    Abstract: Pseudopeptides comprising a peptide of formula I:X-A.sup.1 -A.sup.2 -Trp-Ala-Val-Gly-His-Leu-.sub.psi -A.sup.9 -Qwherein X is hydrogen, a single bond linking the alpha amino group of A.sup.1 to the gamma carboxyl moiety on the 3-priopionyl moiety of A.sup.2 when A.sup.2 is Glu, or a group of formula R.sup.1 CO-- wherein R.sup.1 is selected from the groups consisting ofa) hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.1-10 -alkyl, p-HI-phenyl, p-HI-phenyl-C.sub.1-10 -alkyl, naphthyl, naphthyl-C.sub.1-10 -alkyl, indolyl, indolyl-C.sub.1-10 -alkyl, pyridyl, pyridyl-C.sub.1-10 -alkyl, thienyl, thienyl-C.sub.1-10 -alkyl, cyclohexyl or cyclohexyl-C.sub.1-10 -alkyl, where HI=F, Cl, Br, OH, CH.sub.3 or OCH.sub.3 ;b) N(R.sup.2)(R.sup.3)--, wherein R.sup.2 is hydrogen, C.sub.1-10 alkyl, phenyl or phenyl-C.sub.1-10 -alkyl, R.sup.3 is hydrogen or C.sub.1-10 alkyl; c) R.sup.4 O--, wherein R.sup.4 is C.sub.1-10 alkyl, phenyl or phenyl-.sub.1-10 -alkyl; A.sup.
    Type: Grant
    Filed: March 15, 1993
    Date of Patent: November 29, 1994
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Andrew V. Schally, Renzhi Cai
  • Patent number: 5367052
    Abstract: A biologically active peptide associated with diabetes and designated herein "amylin" and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.
    Type: Grant
    Filed: May 1, 1989
    Date of Patent: November 22, 1994
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Garth J. S. Cooper, Antony C. Willis
  • Patent number: 5366725
    Abstract: The carcinostatic agent of the present invention is an extract from seeds of Aeginetia indica and has interleukin-2 and interferon-.gamma. inducing potency. As shown in FIG. 1, all of the mice, to which this extract was not given, (.DELTA.) died from tumor (6 mice). In contrast, in the mice, to which the extract was given by 0.6 mg/kg (.quadrature.), 1.2 mg/kg (+), and 2.5 mg/kg ( ) intraperitoneally once in every two days from the day of tumor grafting, all mice showed increase in the survival rate. Thus, the extract exhibits excellent carcinostatic effect.
    Type: Grant
    Filed: April 20, 1993
    Date of Patent: November 22, 1994
    Inventors: Shinya Okubo, Mitsunobu Sato, Kunisuke Himeno
  • Patent number: 5364838
    Abstract: A method for treating a patient suffering from diabetes mellitus and a programmed, portable, hand-held device and formulations used in such treatment methodology is disclosed. The programmed device is loaded with a container which includes a formulation comprised of insulin dispersed in a suitable propellant such as a low boiling point propellant. The container may be completely sealed and may be punctured on insertion in the device but preferably includes a single valve which can be opened to release insulin forced from the container by the propellant. A valve for releasing formulation is controlled by an electronic means for opening the valve in response to a measured threshold of airflow which airflow is measured by an airflow detection means positioned between the valve and a mouthpiece. Insulin is administered when the patient inspiratory flow exceeds a preset threshold.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: November 15, 1994
    Assignee: Miris Medical Corporation
    Inventor: Reid M. Rubsamen
  • Patent number: 5364842
    Abstract: A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: November 15, 1994
    Assignee: Neurex Corporation
    Inventors: Alan Justice, Tejinder Singh, Kishor C. Gohil, Karen L. Valentino
  • Patent number: 5364841
    Abstract: The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.
    Type: Grant
    Filed: June 21, 1993
    Date of Patent: November 15, 1994
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Garth J. S. Cooper, Brendan Leighton
  • Patent number: 5364844
    Abstract: Compounds of formula (I): ##STR1## A is a carbon-carbon bond or C.sub.1 -C.sub.3 alkylene; B is imino group or C.sub.1 -C.sub.2 alkylene; R.sup.1 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, heterocyclic or optionally substituted amino; R.sup.2 is optionally substituted phenyl or optionally substituted naphthyl; R.sup.3 is thiazolyl, isoxazolyl or imidazolyl; R.sup.4 is isopropyl or cyclohexyl; R.sup.5 and R.sup.6 are C.sub.1 -C.sub.4 alkyl, or, together with the carbon atom to which they are attached, C.sub.3 -C.sub.7 cycloalkyl; R.sup.7 is hydrogen, optionally substituted C.sub.1 -C.sub.6 alkyl group; and R.sup.8 is hydrogen or C.sub.1 -C.sub.4 alkyl. These compounds have renin-inhibitory and, hence, hypotensive activities. The invention also provides a method for the treatment or prophylaxis of hypertension induced by failures in the renin-angiotensin system.
    Type: Grant
    Filed: August 27, 1992
    Date of Patent: November 15, 1994
    Assignee: Sankyo Company, Limited
    Inventors: Yasuhiro Morisawa, Mitsuru Kataoka, Yuichiro Yabe, Hiroyuki Koike, Yasuteru Iijima, Hidekuni Takahagi, Tatsuo Kokubu, Kunio Hiwada
  • Patent number: 5364930
    Abstract: The invention provides a fragment of Clq which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: ##STR1## or variants thereof capable of binding immunoglobulin. Like the Clq fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid.
    Type: Grant
    Filed: October 16, 1990
    Date of Patent: November 15, 1994
    Assignee: Northwestern University
    Inventors: Michael A. Baumann, Byron E. Anderson
  • Patent number: 5364840
    Abstract: Synthetic hypocalcemic peptides which are superior in biological properties to native calcitonins as clinically useful agents. The peptides comprise analogues of native calcitonins having amino acid additions at the N-terminal position which, either alone or together with substitutions, and deletions at other residues, act to improve potency, prolong duration of the hormonal effect, and increase oral or nasal bioavailability. Methods are provided for the synthesis of these peptides.
    Type: Grant
    Filed: June 5, 1991
    Date of Patent: November 15, 1994
    Assignee: Vical, Inc.
    Inventors: Channa Basava, Karl Y. Hostetler
  • Patent number: 5362855
    Abstract: An imidoester, cross-linked hemoglobin composition useful in the transport of oxygen to living cells and being essentially free of any impurities, a P50 of at least 13 mm Hg and predominantly in tetramer form. Preferably, the cross-linked hemoglobin composition has a predominant molecular weight of at least 64,000. The purified and cross-linked hemoglobin has improved cross-link stability to autoxidation and can be used as a blood substitute for mammals or as an oxygen transport fluid.
    Type: Grant
    Filed: May 20, 1993
    Date of Patent: November 8, 1994
    Assignee: The Upjohn Company
    Inventors: Robert L. Garlick, Stephen B. Lyle, Joseph P. Martin, Jr.
  • Patent number: 5362851
    Abstract: The present invention relates, by way of novel industrial products, to peptide compounds selected from the group consisting of(i) the tripeptides of the formulaY--A.sub.1 --A.sub.2 --A.sub.3 --R (I)in whichY is H or an appropriate group blocking the N-terminal end,A.sub.1 is an amino acid residue selected from the group consisting of (2-oxothiazolidin-4-yl)carbonyl [abbreviated to THC], (2-oxotetrahydro-1,3-thiazin-5yl)carbonyl [abbreviated to TZC], thiazolidine-4-carbonyl [abbreviated to ATC] and (tetrahydro-1,3-thiazin-5-yl)carbonyl [abbreviated to AZC] residues,A.sub.2 is an amino acid residue selected from the group consisting of Pro, 3Hyp and 4Hyp residues, where the OH side-group of 3Hyp and 4Hyp is capable of being protected by an ether or ester protecting group,A.sub.3 is an amino acid residue selected from the group consisting of Arg and Lys residues, andR is a labeling means; and(ii) their addition salts.These novel compounds are useful as substrates in the determination of Protein C.
    Type: Grant
    Filed: October 2, 1991
    Date of Patent: November 8, 1994
    Assignee: Serbio
    Inventors: Gerard Quentin, Jean-Luc Martinoli
  • Patent number: 5360791
    Abstract: The invention relates to compounds of the formula I ##STR1## in which A denotes a radical of the formula II ##STR2## in which E denotes a CH.sub.2 group or an NR.sup.9 radical,G denotes a radical from the group comprising S, SO, SO.sub.2, O, CO, CS or a direct bond,B denotes an amino acid,D denotes a heterocycle andR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.9 are defined in the description, and their salts.The invention in addition relates to a process for the preparation of the compounds of the formula I and their use as pharmaceuticals.
    Type: Grant
    Filed: January 6, 1993
    Date of Patent: November 1, 1994
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Rainer Henning, Hansjorg Urbach, Dieter Ruppert, Bernward Scholkens
  • Patent number: 5358933
    Abstract: Novel peptides are disclosed which are based on the formula:R.sub.1 (Lys-Phe-Leu).sub.n --Rwherein n is an integer of from 1-10 and R and R.sub.1 are H or an amino acid residue or a fatty acid residue which are useful in the treatment of septic shock.
    Type: Grant
    Filed: April 19, 1993
    Date of Patent: October 25, 1994
    Assignee: BiosYnth S.r.l.
    Inventor: Massimo Porro
  • Patent number: 5357042
    Abstract: Peptides comprising fibrin-specific epitopic sequences are used to prepare hybridoma cell lines producing antifibrin-specific monoclonal antibodies substantially devoid of fibrinogen-cross-reactivity obtained by somatic cell fusion. The antibodies are useful for the in vivo and in vitro detection of thrombi and fibrin deposits.
    Type: Grant
    Filed: August 24, 1992
    Date of Patent: October 18, 1994
    Assignee: The General Hospital Corporation
    Inventors: Gary R. Matsueda, Edgar Haber, Kwan Hui
  • Patent number: 5356876
    Abstract: A method of terminating pregnancy in mammals is described by a novel application of the common fertility-promoting hormone known as human menopausal gonadotropin. A single injection of this gonadotropic hormone as early as the first day of conception can terminate pregnancy.
    Type: Grant
    Filed: August 21, 1992
    Date of Patent: October 18, 1994
    Assignee: Trinity university
    Inventor: Lawrence L. Espey
  • Patent number: 5354900
    Abstract: There are disclosed a new peptide .alpha.-hANP of the following structure: ##STR1## and acid addition salt thereof; a diuretic composition and a hypotensor composition containing the .alpha.-hANP or an acid addition salt thereof; and processes for the production thereof.
    Type: Grant
    Filed: December 21, 1984
    Date of Patent: October 11, 1994
    Assignees: Suntory Limited, Hisayuki Matsuo
    Inventors: Hisayuki Matsuo, Kenji Kangawa